Patents by Inventor John E. Murphy
John E. Murphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150307625Abstract: Provided herein are antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human activated Protein C (aPC) with minimal binding to its zymogen Protein C (PC). Moreover, these aPC binding proteins could potentially block the anti-coagulant activity of aPC to induce coagulation. Therapeutic uses of these binders are described herein as are methods of panning and screening specific antibodies.Type: ApplicationFiled: November 27, 2013Publication date: October 29, 2015Applicant: BAYER HEALTHCARE LLCInventors: Xiao-Yan ZHAO, Zhuozhi WANG, Jian-Ming GU, Ji-Yun KIM, Maxine BAUZON, John E. MURPHY, Kirk MCLEAN, Fang JIN, Tobias MARQUARDT, Xinquan WANG, Andreas WILMEN
-
Patent number: 9096656Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.Type: GrantFiled: January 24, 2013Date of Patent: August 4, 2015Assignee: BAYER HEALTHCARE LLCInventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
-
Publication number: 20140271660Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: BAYER HEALTHCARE LLCInventors: YE JIN, JOHN E. MURPHY, TERRY HERMISTON, TIMOTHY MYLES, FRANK DITTMER, MICHAEL STRERATH, UWE GRITZAN
-
Publication number: 20140275493Abstract: Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPI at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: John E. Murphy, Zhuozhi Wang, Ruth Winter
-
Publication number: 20140271661Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Bayer HealthCare LLCInventors: YE JIN, John E. Murphy, Terry Hermiston, Timothy Myler, Frank Dittmer, Michael Strerath, Uwe Gritzan
-
Publication number: 20130274445Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.Type: ApplicationFiled: January 24, 2013Publication date: October 17, 2013Inventors: Clark Q Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
-
Publication number: 20120269817Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: ApplicationFiled: August 4, 2009Publication date: October 25, 2012Applicant: BAYER HEALTHCARE LLCInventors: Zhuozhi Wang, John E. Murphy, Junliang Pan, Haiyan Jiang, Bing Liu
-
Publication number: 20120121613Abstract: The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate.Type: ApplicationFiled: January 19, 2010Publication date: May 17, 2012Applicant: BAYER HEALTHCARE LLCInventors: Liang Tang, Jun Wang, Baisong Mei, John E. Murphy
-
Publication number: 20110286988Abstract: This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking von Willebrand Factor.Type: ApplicationFiled: June 4, 2009Publication date: November 24, 2011Applicant: BAYER HEALTHCARE LLCInventors: Haiyan Jiang, Glenn Pierce, John E. Murphy, Junliang Pan, Xin Zhang, Tongyao Liu
-
Publication number: 20110112022Abstract: The invention relates to modified Factor VIII molecules with reduced N-linked glycosylation and reduced immunogenicity. The invention also relates to methods of using modified Factor VIII molecules, for example, to treat patients afflicted with hemophilia.Type: ApplicationFiled: June 25, 2009Publication date: May 12, 2011Applicant: BAYER HEALTHCARE LLCInventors: Fred Jullien Aswad, Richard Harkins, Hsiao-Lai Liu, John E. Murphy, Faye Wu, Ying Zhu
-
Publication number: 20100240100Abstract: The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods.Type: ApplicationFiled: December 8, 2008Publication date: September 23, 2010Inventors: Toshihiko Takeuchi, Nathalie Dubois-Stringfellow, John E. Murphy, Julie Rinkenberger
-
Publication number: 20100081615Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.Type: ApplicationFiled: August 13, 2009Publication date: April 1, 2010Applicant: Bayer HealthCare LLCInventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
-
Patent number: 7632921Abstract: This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.Type: GrantFiled: November 14, 2005Date of Patent: December 15, 2009Assignee: Bayer Healthcare LLCInventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
-
Patent number: 7462696Abstract: The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP (SEQ ID NO: 118) repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP (SEQ ID NO: 119)). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods.Type: GrantFiled: October 18, 2002Date of Patent: December 9, 2008Assignee: Bayer Pharmaceutical CorporationInventors: Toshihiko Takeuchi, Nathalie Dubois-Stringfellow, John E. Murphy, Julie Rinkenberger
-
Patent number: 7462592Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: GrantFiled: October 22, 2002Date of Patent: December 9, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Patent number: 7214384Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.Type: GrantFiled: May 27, 2003Date of Patent: May 8, 2007Assignee: Novartis Vaccines And Diagnostics, Inc.Inventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
-
Patent number: 6982092Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.Type: GrantFiled: May 30, 2003Date of Patent: January 3, 2006Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
-
Publication number: 20040018962Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.Type: ApplicationFiled: May 27, 2003Publication date: January 29, 2004Applicant: Chiron CorporationInventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
-
Publication number: 20030185890Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: ApplicationFiled: October 22, 2002Publication date: October 2, 2003Inventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Publication number: 20030149595Abstract: Computer-based technologies and methods of human clinical data capture and analysis for identifying and recruiting patients for pharmaceutical and diagnostic product testing. These methods include acquiring product data and clinical data and comparing product data to clinical data in real time in order to identify suitable patients for product testing. Methods also provide for the generation of an alert message identifying suitable patients, preferably through the use of artificial intelligence or neural network techniques. Methods also preferably include the use of wireless devices to collect the patient data with a graphical user interface suitable of displaying the alert message and receiving additional questions for use in querying the patients for collection of data, the encryption of clinical data during transmission and storage, and conversion of clinical data to a format consistent with data mining techniques.Type: ApplicationFiled: February 1, 2002Publication date: August 7, 2003Inventor: John E. Murphy